TACL Decitabine + Vorinostat Epigenetic study in AML

T2016-003: Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML
The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.
CHLA IRB Number
CHLA-17-00209
Study Type
Drug Treatment
Eligibility
Age 1 to 25 with leukemia (AML) that has returned after an initial response to treatment
Clinical Trials Government Identifier
NCT03263936
Enrollment Status
Open
Does this study also recruit healthy volunteers?
No
Coordinator Contact
Ellynore Florendo
Contact Email
TACL@chla.usc.edu
Coordinator Contact
Meg Fender